Skip to main content

Artelo Biosciences, Inc.

ARTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001621221

No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Artelo Biosciences, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of ARTL: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders2218−4
Shares1.90M1.47M−432.4K (−22.8%)
Value$984.0K$659.0K−$325.0K (−33.0%)

New holders (4)

Institutions that held Artelo Biosciences, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to ARTL in Q1 2022
InstitutionSharesValue% of portfolio
Snowden Capital Advisors LLC110,000$49.0K0.00%
HRT Financial LP27,952$12.0K0.00%
UBS Group AG18,283$8.00K0.00%
Keystone Wealth Partners15,000$7.00K0.00%

Sold out (8)

Institutions that held Artelo Biosciences, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of ARTL in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Kepos Capital LP200,000$104.0K
Citadel Advisors LLC78,586$41.0K
Commonwealth Equity Services, LLC27,470$14.0K
Two Sigma Advisers, LP16,000$8.00K
Millennium Management LLC11,977$6.00K
Bank of America Corp46$0
FMR LLC65$0
Global Wealth Management Investment Advisory, Inc.475$0